Examination of the effect by taking the sodium glucose transporter 2 inhibitor everyday or only when a patient thinks it to be necessary for type 2 diabetes patients controlled inadequately.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2016
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 12 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Oct 2015 New trial record